Business Wire

Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022

Share

Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting. Rhizen’s poster presentations describe the preclinical characterization and differentiated features of its novel PARP inhibitor (RP12146) and preclinical data supporting the broad positioning of its DHODH inhibitor (RP7214) in AML.

Rhizen had earlier indicated that its PARP program had demonstrated differentiated IND enabling preclinical safety. The additional preclinical data being presented at AACR 2022 suggests that this differentiated safety may be due to the lower bone marrow distribution of RP12146 and concomitantly lower haematological toxicity. “We believe RP12146’s safety differential has allowed us to progress through the dose escalation study more efficiently. Further, the emerging data from our ongoing phase 1 dose escalation study is encouraging & corroborative with robust target engagement and safety observed so far. We believe that this differentiation, as it translates more fully in the clinic, may allow us to explore the full potential of PARP inhibition across indications given RP12146’s potentially wide therapeutic window,” said Swaroop Vakkalanka, Founder & CEO of Rhizen Pharma.

Rhizen indicated that its DHODH inhibitor, RP7214 has robust activity as a single agent in inducing tumor volume & size reduction and differentiation of AML blasts consistent with its mechanism of action. RP7214 also potentiates the activity of standard of care AML agents such as cytarabine, venetoclax and azacytidine. Swaroop added that “We have initiated a phase 2 study to explore RP7214 in combination with azacytidine in relapsed/refractory AML, CMML and MDS patients. The potential of DHODH inhibition as a therapeutic modality in AML remains unfulfilled and we expect RP7214 can eventually realize that potential. We believe elderly patients who are ineligible for frontline chemotherapy and maintenance settings represent areas of unmet need that RP7214 can address.”

Details on Rhizen Pharma’s posters at AACR are as follows:

  1. Abstract Number: 1762
    Title: Activity of RP7214, a novel, selective, and potent small molecule inhibitor of DHODH, in AML
    Session: Small Molecule Therapeutic Agents
    Poster Number: 5492
  2. Abstract Number: 1766
    Title: Activity of RP12146, a novel, selective, and potent small molecule inhibitor of PARP 1/2, in solid tumors
    Session: Small Molecule Therapeutic Agents
    Poster Number: 5493

About Rhizen Pharmaceuticals AG.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology & inflammation therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.

Rhizen has proven expertise in the PI3K modulator space with the discovery of our first PI3Kδ & CK1ε asset Umbralisib, that has been successfully developed & commercialized in MZL & FL by our licensing partner TG Therapeutics (TGTX) in USA. Rhizen is also developing Tenalisib, a unique dual PI3K-δ/γ & SIK3 inhibitor with a robust safety profile and promising activity in metastatic breast cancer and T-Cell lymphoma indications. Behind these assets, Rhizen has a deep oncology & inflammation pipeline spanning discovery to clinical development stages.

Rhizen is headquartered in Basel, Switzerland. For additional information, please visit https://www.rhizen.com/

Safe Harbor

This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rhizen Pharmaceuticals AG - Contact:
Samyukta Bhagwati
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals AG.
Telephone: +41 32 580 0113
Email: corpcomm@rhizen.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF to Webcast Fireside Chat at Bernstein Strategic Decisions Conference on June 124.5.2022 23:15:00 EEST | Press release

IFF (NYSE: IFF) today announced that Chief Executive Officer Frank Clyburn will participate in a fireside chat at the Bernstein 2022 Strategic Decisions Conference on Wednesday, June 1, 2022 at 8 am ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. View source version on busine

HCL Commits $15 Million to Address Global Freshwater Insecurity24.5.2022 20:16:00 EEST | Press release

Water security has never been more urgent. With the global population set to hit 8.5 billion by 2030, pressure is increasing on the world’s limited supply of freshwater. By 2030, the global demand for water will have exceeded sustainable supply by 40%. In addition to immediate and dire consequences to people’s health and food production, a lack of access to clean water can limit economic growth by up to one-third, as well as have adverse effects on natural biodiversity and social fabrics. Governments and businesses must bring freshwater to the forefront of their strategies, and innovation will play a key role in their success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005757/en/ People in the picture (from left) – Roshni Nadar Malhotra, CEO, HCL Group & Chairperson, HCL Technologies; Gim Huay Neo, Managing Director, Centre of Nature and Climate, World Economic Forum; William Kwende, Founder of Serious Shea; Inna M

Alcineo Deploys Verimatrix Threat Defense Technology To Protect SoftPOS Terminal Solutions for Banks, Payment Providers24.5.2022 18:45:00 EEST | Press release

Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced its Verimatrix Code Shield was deployed by La Ciotat, France-based Alcineo to protect its best-in-class SoftPOS solutions that are used by banks and payment solutions providers to offer Tap on Phone payments from any contactless card or mobile wallet. As part of Verimatrix’s threat defense offerings, Verimatrix Code Shield plays a pivotal role in progressing the certification process for Alcineo’s SoftPOS SDK, that serves transporation for fare inspection and ticket selling or retail for queue boosting. This SDK also facilitates charity donation and combines contactless payment and digital vouchers acceptance at restaurants. Verimatrix Code Shield works with Alcineo’s solutions that currently hold international payment scheme certifications such as Visa and Mastercard. Domestic payment networks are also supported. “Allowing pay

Linksys Brings Best in Class WiFi Performance to the Home with New Series of Affordable WiFi 6 Mesh Solutions24.5.2022 18:00:00 EEST | Press release

Linksys, a global leader in home and business WiFi networking solutions, today announced two new WiFi 6 mesh systems designed to deliver peak wireless performance for all at-home needs including remote working, streaming content, multi-user gaming and more. The Linksys Hydra 6 and Linksys Atlas 6 are Linksys’ newest entry-level dual-band products in the company's family of WiFi 6 mesh systems and come at the most affordable prices to date for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005310/en/ Linksys Atlas 6 (Photo: Business Wire) “There is an increased need for wireless connectivity that can handle the influx of devices on home networks, and deliver reliable, secure and private connections,” said Alan Cohen, VP of Marketing and Head of Product at Linksys. “Our mission is to connect everyone securely and through the launch of these systems, we provide our customers with two new options for fast speed,

Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic24.5.2022 18:00:00 EEST | Press release

Ferring Pharmaceuticals today announced the presentation of four abstracts at Digestive Disease Week (DDW) 2022 that further characterize RBX2660, a potential first-in-class microbiota-based live biotherapeutic studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection (CDI) after antibiotic treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005036/en/ Two of these abstracts reviewed data from PUNCH™ CD clinical program and included subgroup analyses on the potential of RBX2660 to reduce CDI recurrence consistently and safely in adults regardless of their baseline characteristics. The first abstract (RBX2660 Versus Placebo to Reduce the Recurrence of Clostridioides Difficile Infection: Subgroup Analysis; Session number 892), an oral presentation, was a subgroup analysis of integrated data from randomized participants who received one dose of blinded treatment

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom